ArticleThe Journal of clinical and aesthetic dermatology2024
Postpartum Telogen Effluvium Unmasking Additional Latent Hair Loss Disorders.
Article in The Journal of clinical and aesthetic dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Translating umbilical cord blood extracellular vesicles into a novel therapy for postpartum alopecia: a mechanistic and preclinical review.Frontiers in immunology · 2026Review
- Particulate matter exposure induces maternal scalp hair loss after birth in C57/B6 mouse via alteration of inflammatory and apoptotic pathways.Frontiers in endocrinology · 2026Article
- Research Trends and Hotspots in Female Pattern Hair Loss: A Bibliometric Study.Journal of cosmetic dermatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obejctive: We sought to detect additional underlying hair loss disorders in patients with postpartum telogen effluvium. Methods: We completed clinical and dermoscopic evaluations on 200 female participants experiencing postpartum hair loss. Results: 9.5 percent of patients were diagnosed with telogen effluvium (TE), 56.0 percent patients were diagnosed with TE with androgenetic alopecia (AGA), 6.5 percent patients were diagnosed with TE and TA, and 28.0 percent patients were diagnosed with TE, AGA, and TA. In the central area, patients with TE displayed upright regrowing hair and single pilosebaceous unit in 100 percent and 94.7 percent of patients, respectively. While patients with TE and AGA, displayed upright regrowing hair, single pilosebaceous unit, and hair diameter diversity greater than 20 percent. In patients diagnosed with TE and TA, the trichoscopic findings were similar in the TE group to the patients diagnosed with TE, AGA, and TA were also similar to the patients with TE and AGA. Regarding the area of traction, there was no difference observed between the patients with TE and TA and patients with TE, AGA, and TA. The frequent findings were hair diameter diversity, empty follicles, and vellus hair. Conclusion: Postpartum TE may be associated with other hair loss disorders. Awareness of this is critical to appropriate diagnosis and treatment.
Indexed as
Identifiers
38779373PMC11107900What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.